I-Mab Biopharma

Contributing Author

Recent Articles by I-Mab Biopharma

Oct-22	I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 IMAB GlobeNewswire
Oct-16	I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences IMAB GlobeNewswire
Oct-14	I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference IMAB GlobeNewswire
Sep-08	I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments IMAB GlobeNewswire
Aug-25	I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee IMAB GlobeNewswire
Aug-21	I-Mab to Participate in September Investor Conferences IMAB GlobeNewswire
Aug-20	I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update IMAB GlobeNewswire
Aug-11	I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers IMAB GlobeNewswire
Aug-01	I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares IMAB GlobeNewswire
Jul-17	I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health IMAB GlobeNewswire
Jul-14	I-Mab to Present at the BTIG Virtual Biotechnology Conference IMAB GlobeNewswire
Jul-02	I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 IMAB GlobeNewswire
Jun-30	I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research IMAB GlobeNewswire
Jun-26	I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 IMAB GlobeNewswire
Jun-18	I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025 IMAB GlobeNewswire
Jun-12	I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement IMAB GlobeNewswire
Jun-03	I-Mab to Participate in the H.C. Wainwright "HCW@Home" Series IMAB GlobeNewswire
May-20	I-Mab to Present at Jefferies Global Healthcare Conference IMAB GlobeNewswire
May-15	I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update IMAB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.